ART-123: Recombinant human soluble thrombomodulin

Cardiovascular Drug Reviews

Volumn 18, Issue 4, 2000, Pages 312-325

  Mohri, Mitsunobu ^a  

^a ASAHI CHEMICAL INDUSTRY CO   (Japan)

Author keywords

ART 123; Deep venous thrombosis; Disseminated intravascular coagulation; Soluble thrombomodulin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; PROTEIN C; RECOMBINANT THROMBOMODULIN; THROMBIN;

BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0034523299     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2000.tb00055.x     Document Type: Review

References (57)

1. Effects of recombinant human soluble thrombomodulin (rhs-TM) on disseminated intravascular coagulation model in the rats with decreased plasma antithrombin III level
2. Antithrombotic effects of recombinant human soluble thrombomodulin (rhs-TM) on arteriovenous shunt thrombosis in rats
3. Recombinant human soluble thrombomodulin delivers bounded thrombin to antithrombin III: Thrombomodulin associates with free thrombin and is recycled to activate protein C
4. Kinmase and vascular responses to kinins
5. TAFI or plasma carboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
6. Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation
7. Carboxypeptidase M-like enzyme modulates the noncholinergic bronchoconstrictor response in guinea pig
8. The regulation of natural anticoagulant pathways
9. The roles of protein C and thrombomodulin in the regulation of blood coagulation
10. Recombinant human activated protein C improves coagulation abnormalities, morbidity and 28 day mortality in patients with sever sepsis
11. Thrombin activity of fibrin thrombi and soluble plasmic derivatives
12. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex
13. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice
14. Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats
15. Selective effects of protein C on activation of human monocytes by lipopolysaccaride, interferon-gamma, or PMA: Modulation of effects on CD11b and CD14 but not CD25 or CD54 induction
16. Selective inhibitory effects on the anti-coagulant activated protein C on the response of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester
17. Inhibition of thrombus formation by activated protein C in a primate model of arterial thrombosis
18. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses
19. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates
20. Antithrombotic efficacy and safety of recombinant human soluble thrombomodulin in non-human primates: Inactivation of thrombin and enhanced generation of activated protein C
21. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
22. The roles played by the D2 and D3 domains of recombinant human thrombomodulin in its function
23. In vitro studies on the effect of activated protein C on platelet activation and thrombin generation
24. Purification of rabbit. Rat and mouse protein C with the use of monoclonal antibody to human protein C. PC01
25. Comparative study of protein C activators from the Agkistrodom snake venoms
26. The influence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin
27. Bradykinin, a new potential mediator of inflammation-induced bone resorption. Studies of the effects on mouse calvarial bones and articular cartilage in vitro
28. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation
29. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics and on syncytiophoblast of human placenta
30. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis)
31. Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats
32. Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin
33. The inhibitory effect of recombinant human soluble thrombomodulin on initation and extension in coagulation. A comparison with other anticoagulants
34. Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma
35. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats
36. Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin. ART-123. In healthy male volunteers
37. A novel recombinant human soluble thrombomodulin, ART-123. Activates the ptotein C pathway in healthy male volunteers
38. The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-reduced disseminated intravascular coagulation
39. Evidence that the protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma
40. Blood clotting in minimally altered whole blood
41. Coagulation factor V: An old star shines again
42. On the mechanism of the antifibrinolytic activity of plasma carboxypeplidase B
43. Isolation and characterization of thrombomodulin from human placenta
44. Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor
45. A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation
46. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation
47. A thrombin-based peptide corresponding to the sequence of the thrombomodulin-binding site blocks the procoagulant activities of thrombin
48. In vitro anticoagulant properties of a minimum functional fragment of human thrombomodulin and in vivo demonstration of its benefit as an anticoagulant in extracorporeal circulation using a monkey model
49. Neuroprotection by recombinant thrombomodulin
50. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon
51. Cleavage requirements of factor V in tissue-factor induced thrombin generation
52. rhs-TM prevents ET-reduced increase in pulmonary vascular permeability through protein C activation
53. Recombinanl thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation
54. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation
55. Clot-bound thrombin is protected from inhibition by heparin - Antithrombin III - But is susceptible to inactivation by antithrombin III - Independent inhibitors
56. 2+-mediated binding to protein C
57. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity